TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04148404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermic group
Description: 1. Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~2. Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermic group
Description: 1. Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~2. Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).
Study: NCT00896064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A (formulation 1)
Description: One dose will be administered intramuscularly at Study Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A (formulation 2)
Description: One dose will be administered intramuscularly at Study Day 0.
Study: NCT03345797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Nasal Gel [Natesto]
Description: nasal gel containing 4.5% w/w testosterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Nasal Gel [Natesto]
Description: nasal gel containing 4.5% w/w testosterone
Study: NCT02896166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: eligible patients will be treated with microwave ablation in the primary tumor sites
Study: NCT02025075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
Study: NCT02517723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behavior Therapy
Description: Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.~Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Inpatient Care
Description: Unspecific group therapy that is identical in both groups (music therapy etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Inpatient Care
Description: Unspecific group therapy that is identical in both groups (music therapy etc.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting List
Description: Treatment as usual in the community (no DBT, no exposure of trauma memories)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting List
Description: Treatment as usual in the community (no DBT, no exposure of trauma memories)
Study: NCT00383526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated, split-virion influenza vaccine
Description: Vaccine
Study: NCT01653691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse-Dye Laser
Description: Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No treatment to one side of subject's scar.
Study: NCT02999685

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-base Pulmonary Rehab with Health Coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-base Pulmonary Rehab with Health Coaching
Study: NCT04666623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esketamine nasal spray
Description: unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
Study: NCT01620268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide and orotic acid
Description: Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
Study: NCT04662333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcrestal approach for sinus lift
Description: After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcrestal approach for sinus lift
Description: After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Xenograft application
Description: Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
Study: NCT03189082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbotox
Description: Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
Study: NCT00083915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 20mg/m2 continuous infusion days -3 and -2.
Study: NCT01901432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: In Part A patients will treated in dose levels at the following daily doses of Givinostat:~* 50 mg b.i.d.,~* 100 mg b.i.d.;~* 150 mg b.i.d.,~* 200 mg b.i.d.;~* 150 mg t.i.d.;~* 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
Study: NCT04579718

Intervention type: OTHER
Intervention: Zeus Cloud TPS V1.0
Description: Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.

Intervention type: OTHER
Intervention: Eclipse
Description: Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.
Study: NCT00083915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 800 mg/m2 continuous infusion days -3 and -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: 20mg/m2 continuous infusion -3 and -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 80mg/m2 continuous infusion -3 and -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: 200mg PO Continuing to Day +5, then hold until platelets \>50 thousand (K).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg po days 1 - 4 (4 days)
Study: NCT01276977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolmitriptan 5 mg Nasal Spray
Description: Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg Nasal Spray
Description: Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eletriptan 40 mg tablet
Description: Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg tablet
Description: Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
Study: NCT03913962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: indirect calorimetry
Description: Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: indirect calorimetry
Description: Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
Study: NCT00551369

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
Study: NCT01066234

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy
Description: weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy only
Description: four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
Study: NCT02675166

Intervention type: OTHER
Intervention: Pediatric cancer young adult survivors
Description: Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
Study: NCT00912366

Intervention type: PROCEDURE
Intervention: Lobectomy
Description: Assessment of VATS versus open surgery.

Intervention type: PROCEDURE
Intervention: Lobectomy
Description: Assessment of VATS versus open surgery.
Study: NCT03287544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined rehabilitation
Description: Linguistic training as well as communication training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Linguistic rehabilitation
Description: Rehabilitation only focused on linguistic processes.
Study: NCT00834184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nikkomycin Z
Description: Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nikkomycin Z
Description: Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.
Study: NCT01241487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan/amlodipine
Description: 160/10 mg
Study: NCT00834184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nikkomycin Z
Description: Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.
Study: NCT02333305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: • 2 dosages according to patient weight: Weight \< 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sanomit Placebo
Description: • according to patient weight: Weight \< 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
Study: NCT01192464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous CAR.CD30 EBV specific-CTLs
Description: Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
Study: NCT03360734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)
Description: Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
Study: NCT01790399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of sentinel node(s)
Description: Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
Study: NCT00719901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03953716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level light therapy
Description: Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DING KUN DAN
Description: DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulated drug of DING KUN DAN
Description: Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
Study: NCT04716777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Transdiagnostic group-based Cognitive-Behavioral Treatment
Description: Weekly group-based transdiagnostic CBT sessions for eight weeks.
Study: NCT02349386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHR-200 (0.36% transdermal 17β-estradiol gel)
Description: An absorptive hydroalcoholic gel preparation containing 17β-estradiol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHR-200 (0.36% transdermal 17β-estradiol gel)
Description: An absorptive hydroalcoholic gel preparation containing 17β-estradiol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHR-200 (0.36% transdermal 17β-estradiol gel)
Description: An absorptive hydroalcoholic gel preparation containing 17β-estradiol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
Study: NCT01847677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT02033798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Once Daily 0.2mg per oral for 6 months
Study: NCT00091819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10 mg/kg/day, IV for up to 14 days.
Study: NCT01847677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT02952118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forrest Snoring device
Study: NCT04695522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADR-002K administration
Description: ADR-002K administration

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ADR-002K administration
Description: ADR-002K administration
Study: NCT03561662

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpro soya drinks
Description: 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpro soya drinks
Description: 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpro soya drinks
Description: 12 weeks
Study: NCT02243111

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Detecting Doppler signals from the lungs on the right chest wall
Study: NCT02389452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synvisc-One
Description: intraarticular injection
Study: NCT01134172

Intervention type: BEHAVIORAL
Intervention: survey web-based or telephone interview
Description: Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.

Intervention type: BEHAVIORAL
Intervention: survey web-based or telephone interview
Description: Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. All three follow-up contact methods (email, postcard, call) contain the same question regarding current employment status with minor modifications in formatting. However, the employment question asked in all three follow-up contact methods is shown in the Postcard_Template document. Due to the recent COVID-19 pandemic study staff will be working from home. Therefore, calls will be made via MSK-approved platforms (e.g. Jabber, etc.). Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs. The data collected for these internal tracking logs will be managed through a REDCap database.